Special Report: IPX203 as New Treatment for Parkinson Disease
Movement disorder experts Robert Hauser, MD, MBA, and Hubert Fernandez, MD, discuss the recently approved IPX203 (Crexont; Amneal Pharmaceuticals) for the treatment of patients with Parkinson disease.
EP. 1: Significance of Newly Approved IPX203 for Parkinson Disease
August 12th 2024In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.
EP. 5: Properly Integrating Newly Approved IPX203 in the Care of Parkinson Disease
August 14th 2024The panelists provided clinical insight on the utilization of IPX203, its potential benefits and clinical implications, as well as the practicalities of transitioning patients from other therapies.
